biOasis Technologies Ord Shs BIOAF

If Prothena's PRX012 is an xB3 drug, then...

[Boomskid]

It's true that Prothena's PRX012 could have been modified with xB3 before IND submissions, etc., and it could have been done without disclosure by either Prothena or Bioasis. 

 

If xB3 is a part of PRX012, and if Rathjen is allowing Bioasis to fail without revealing that xB3 is working as hoped, then Bioasis shareholders are watching Bioasis fail without being adequately informed.

 

That has meaning and LET ME SHOUT IT:

 

IF AN xB3 DRUG IS CURRENTLY IN CLINICAL TRIALS AND BIOASIS WAS BEING SOLD TO MIDATECH WITHOUT SHAREHOLDERS KNOWING THAT xB3 WORKS AS HOPED, THEN BIOASIS  SHAREHOLDERS ARE BEING TREATED IN A MANNER THAT SOME MAY CONSIDER TO BEING SWINDLED.

 

FURTHER, IF AN xB3 DRUG IS IN CLINICAL TRIALS AND THAT IS NOT BEING REPORTED, THEN THE MARKET IS VALUING BIOASIS AS A FAILURE AT 1 CENT WITHOUT INVESTORS HAVING ENOUGH INFORMATION TO PROPERLY EVALUATE THE COMPANY.

 

If that's not BREAKING THE RULES then I'd like to know what it is.

 

So, what kind of bet on BTI should be made if it is suspected that PRX012 is an xB3 drug? Should we be buying BTI at these prices? Were Ladenburg Thalmann and their clients aware of xB3 success about which Bioasis shareholders had no knowledge?

 

If this Prothena thing is true, then what kind of CEO would keep that secret? Why couldn't the CEO make a statement? She could communicate something like the following:

 

"Bioasis announced today that an xB3 drug has shown significant preliminary success and is now in human clinical trials. The type and nature of the drug, its target disorder, and the drug's owner cannot be revealed under the terms of the licensing agreement between Bioasis and the company that is advancing the drug. Bioasis is very encouraged by the success that xB3 is showing, etc., etc."

Sooner or later, Bioasis would have to make a similar statement about some other company 

So, is xB3 actually working? If PRX012 is an xB3 drug and if it works, then what should the Bioasis share price be? What about the "shelved" xB3-001?

Is Bioasis really worth only 1 cent?

It's time to light this candle!

jd
 

[Boomskid]

If Prothena's PRX012 is an xB3 drug, then because Alzheimer's is a chronic disease that will likely require lifetime treatments, then we'll learn whether potential prolonged off-target delivery of an xB3 drug to LRP-1 receptors in the CNS might be a problem or not. That might dispel concerns, if they exist, that using that receptor is problematic as suggested by the piece I wrote about